Simcere Pharmaceutical Group Limited
SMHGF
$0.6697
-$0.0641-8.74%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 878.26M | 904.58M | 934.88M | 966.34M | 1.01B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 878.26M | 904.58M | 934.88M | 966.34M | 1.01B |
| Cost of Revenue | 201.77M | 215.32M | 229.89M | 228.29M | 228.92M |
| Gross Profit | 676.49M | 689.26M | 704.98M | 738.05M | 779.31M |
| SG&A Expenses | 378.96M | 390.68M | 404.16M | 425.74M | 452.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -19.34M | -19.86M | -20.47M | -21.78M | -23.33M |
| Total Operating Expenses | 748.77M | 789.79M | 834.51M | 874.43M | 924.09M |
| Operating Income | 129.49M | 114.79M | 100.37M | 91.91M | 84.14M |
| Income Before Tax | -150.59M | -18.90M | 116.50M | 284.93M | 455.27M |
| Income Tax Expenses | 1.79M | 2.82M | 3.92M | 3.49M | 2.96M |
| Earnings from Continuing Operations | -152.38 | -21.73 | 112.58 | 281.45 | 452.31 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 0.00 | 57.90K | 117.20K | 277.10K | 443.10K |
| Net Income | -152.38M | -21.67M | 112.69M | 281.73M | 452.75M |
| EBIT | 129.49M | 114.79M | 100.37M | 91.91M | 84.14M |
| EBITDA | 159.06M | 144.67M | 130.67M | 122.29M | 114.90M |
| EPS Basic | -0.06 | -0.01 | 0.04 | 0.11 | 0.17 |
| Normalized Basic EPS | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 |
| EPS Diluted | -0.06 | -0.01 | 0.04 | 0.11 | 0.17 |
| Normalized Diluted EPS | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 |
| Average Basic Shares Outstanding | 10.30B | 10.37B | 10.43B | 10.45B | 10.47B |
| Average Diluted Shares Outstanding | 10.30B | 10.38B | 10.46B | 10.48B | 10.50B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -38.04% | -267.55% | 51.44% | 20.05% | 12.39% |